Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study

A Randomized Controlled Trial of the HeartMate 3 and HeartMate II Cardiac Pump

Paolo C. Colombo, MD, Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Jerry D. Estep, MD, Christopher Salerno, MD, Ulrich P. Jorde,

MD, Jennifer A. Cowger, MD, Joseph C. Cleveland, Jr., MD, Nir Uriel, MD, Gabriel Sayer, MD, Eric R. Skipper, MD, Francis X. Downey,

MD, Masahiro Ono, MD, PhD, Robert Hooker, Jr, MD, Anelechi C. Anyanwu, MD, Michael M. Givertz, MD, Claudius Mahr, DO, Ia Topuria,

MPH, Sami I. Somo, PhD, Daniel L. Crandall, PhD, Douglas A. Horstmanshof, MD



ClinicalTrials.gov: NCT02224755



Relevant Financial Relationship Disclosure Statement

Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Clinical Trial: Analysis of the Full Cohort


Presenter: Daniel Goldstein, MD

I WILL NOT discuss off label use and/or investigational use of drugs/devices

The following relevant financial relationships exist related to this presentation:

D. Goldstein	Educator and Surgical Proctor, Consultant – Abbott,
	National Principal Investigator - NIH-VEST Trial,
	Consultant -Terumo Inc.
M. Mehra	Consultant (paid to B&W Hospital) - Abbott, Consultant - Portola, Bayer, Xogenex,
	Steering Committee - Medtronic, Janssen, DSMB - Mesoblast,
	Scientific Advisory Board - NupulseCV, FineHeart
N. Uriel	Consultant - Abbott, Medtronic
J. Cleveland	Consultant - Abbott

HeartMate 3 LVAS



- Wide blood-flow passages to reduce shear stress
- Frictionless with absence of mechanical bearings
- Intrinsic Pulse designed to reduce stasis and avert thrombosis



Mehra et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med 2017;376(5):440-50. Bourque et al. Design Rationale and Preclinical Evaluation of the HeartMate 3 Left Ventricular Assist System for Hemocompatibility. ASA/O J 2016;62(4):375-83




- MOMENTUM 3 is a randomized controlled trial of the HM3 centrifugal-flow pump versus the HMII axial-flow pump in patients with advanced heart failure, irrespective of intended goal of support (bridge-to-transplantation or destination therapy)
- Key exclusion criteria included planned biventricular support, irreversible end-organ dysfunction, or active infection



Heatley et al. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant. 2016;35(4):528-36.

MOMENTUM 3 - Study Design






¹Mehra et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med 2017;376(5):440-50.

Long Term Cohort (N=366) - Primary End Point Analysis (ITT)

Survival at 2 years free of disabling stroke (>3 mRS) or

reoperation to replace or remove a malfunctioning device






mRS denotes modified Rankin Score; CI, confidence interval

Mehra et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med 2018;378:1386-1395.

Key Adverse Events Stroke



MOMENTUM 3

HR denotes hazard ratio; CI, confidence interval

Mehra et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med 2018;378:1386-1395.

Study Objectives

- To evaluate the patterns and provide a time-dependent comparison of stroke events in HM3 vs. HMII patients over 2-years
- 2. To conduct an exploratory analysis of clinical predictors of stroke events
- 3. To assess clinical outcome of strokes by
 - Starting with the first event and initial presentation
 - Comparing the **subtypes** (ischemic stroke (IS) vs. hemorrhagic stroke (HS))
 - Evaluating the severity of neurologic deficit (disabling, modified Rankin Scale (mRS)>3 vs. nondisabling, mRS≤3)






	Hear	:Mate 3 (n =	189)	Heart	Mate II (n =	172)
	EPPY	Patients (%)	Events	EPPY	Patients (%)	Events
Stroke Events	0.08	19 (10.1)	22	0.18	33 (19.2)	43
Stroke by Subtype						
<u>Hemorrhagic</u> Stroke	0.03	8 (4.2)	8	0.07	16 (9.3)	17
<u>Ischemic</u> Stroke	0.05	12 (6.3)	14	0.11	23 (13.4)	26




Disabling Stroke

At Initial Presentation




mRS Adjudicated at 60-Days





Non-Disabling Stroke



MOMENTUM 3

11

Baseline	Не	artMate 3 (n = 18	9)	Не	artMate II (n = 17	2)
Characteristics	No Stroke	Stroke	p-value	No Stroke	Stroke	p-value
	n=170	n=19		n=139	n=33	
Age - years	60 ± 12	67 ± 8	0.001	59 ± 13	60 ± 9	0.53
Gender (Male)	135 (79%)	14 (74%)	0.56*	115 (83%)	25 (76%)	0.35
Destination Therapy	100 (59%)	11 (58%)	0.94	87 (63%)	19 (58%)	0.59
BSA - m ²	2.1 ± 0.3	2.0 ± 0.2	0.05	2.0 ± 0.3	2.1 ± 0.2	0.61
BMI - kg/m²	29.3 ± 6.3	26.7 ± 5.2	0.09	28.1 ± 5.9	29.4 ± 5.3	0.23
Ischemic Etiology	72 (42%)	8 (42%)	0.98	67 (48%)	17 (52%)	0.73
Baseline Blood Pressure – mmHg						
MAP	81 ± 11	82 ± 10	0.63	78 ± 10	80 ± 10	0.48
Systolic	110 ± 16	109 ± 12	0.81	105 ± 13	111 ± 14	0.04
Diastolic	67 ± 11	70 ± 10	0.19	66 ± 11	65 ± 11	0.85
INTERMACS profile			0.30*			0.77
1-2-3	148 (87%)	15 (79%)		115 (83%)	28 (85%)	
4-5	22 (13%)	4 (21%)		24 (17%)	5 (15%)	
Medical History						
Atrial Fibrillation	70 (41%)	11 (58%)	0.16	69 (50%)	12 (36%)	0.17
Diabetic	44 (26%)	2 (11%)	0.17*	22 (16%)	6 (18%)	0.74
Stroke or TIA	26 (15%)	6 (32%)	0.10*	19 (14%)	9 (27%)	0.06
Hypertension (requiring medication)	114 (67%)	12 (63%)	0.73	91 (65%)	24 (73%)	0.43
Known PFO	10 (6%)	2 (11%)	0.34*	18 (13%)	1 (3%)	0.13*
Carotid Artery Disease	92 (54%)	10 (53%)	0.90	70 (50%)	23 (70%)	0.045
Creatinine - mg/dl	1.4 ± 0.4	1.4 ± 0.4	0.95	1.3 ± 0.4	1.4 ± 0.3	0.21
BUN - mmol/l	28 ± 14	31 ± 18	0.36	26 ± 12	30 ± 12	0.13
Bilirubin - mg/dl	1.0 ± 0.5	1.2 ± 0.6	0.09	1.1 ± 0.5	1.0 ± 0.5	0.41

BMI – Body Mass Index; BSA – Body Surface Area; LVEF – Left Ventricular Ejection Fraction; PFO – patent foramen ovale; TIA – Transient Ischemic Attack. *Fishers Exact Test; †Includes Asian, Native Hawaiian or Pacific Islanders, and Others



Stroke Rates Across the Duration of Support

Time (Days)		e Events s on-going, %)	Event: patient		Favors Favors	Odds Ratio (HM3 vs HMII)
	HM3	HMII	НМЗ	HMII	$ \begin{array}{c} HM3 \\ 0 \\ 1 \\ 2 \\ 3 \end{array} $	OR (95% CI)
Overall (0-733 Days)	22 (19/189, 10%)	43 (33/172, 19%)	0.08	0.18	⊢ ●—-1	0.47 (0.26 - 0.86), p=0.01
- Perioperative (0-30 Days)	7 (7/189, 3.7%)	6 (6/172,3.5 %)	0.46	0.44	F	1.06 (0.35 - 3.23), p=0.91
- Short-term (31-180 Days)	7 (7/182, 3.8%)	16 (13/161, 8.1%)	0.10	0.26	⊢ ∎i	0.46 (0.18 - 1.17), p=0.09
- Long-term (181-730 Days)	8 (5/165, 3.0%)	21 (17/141, 12.1%)	0.04	0.13	⊧● 1	0.23 (0.08 - 0.63), p=0.01



Univariable Modeling – Stroke vs. No Stroke

Variable	Stroke (n=52)	No Stroke (n=309)	p-Value
Gender (Male)	39/52 (75%)	250/309 (81%)	0.33
Age (>65)	22/52 (42%)	119/309 (39%)	0.60
Destination Therapy	30/52 (58%)	187/309 (61%)	0.70
Randomization (HM3 Arm)	19/52 (37%)	139/309 (45%)	0.02
History of Stroke or TIA	13/52 (25%)	49/309 (16%)	0.11
Atrial Fibrillation	23/52 (44%)	139/309 (45%)	0.92
Left Atrial Appendage Closure	3/52 (6%)	24/309 (8%)	0.61
Mean Arterial Pressure at Discharge*	83.2 ± 11.2 (37)	80.4 ± 9.1 (288)	0.09
Mean Arterial Pressure (>95 mmHg, baseline preop)	5/51 (10%)	26/309 (8%)	0.74
Gastrointestinal Bleeding ⁺	11/52 (21%)	78/309 (25%)	0.53
Infection ⁺	26/52 (50%)	165/309 (53%)	0.65
Suspected Pump Thrombosis ⁺	5/52 (10%)	19/309 (6%)	0.36
Aspirin at 30 Days§	30/39 (77%)	265/309 (86%)	0.15
INR at 30 Days§	2.2 ± 0.7(39)	2.3 ± 0.8 (296)	0.51


*Excludes strokes occurring pre-discharge +For the stroke group only adverse events (GI Bleeding, Infection, and Suspected Pump

Thrombosis) that occurred prior to the first stroke were included. Prior to stroke only - exclude any events occurring after last stroke event

(include if it is between stroke events because it could have influenced the next stroke). §Excludes patients with strokes prior to 30 Days.



Multivariable model






Adjudicated Causes of Death in Stroke Patients

	Deaths n=23/52 (44%)	Days Post-Implant	Days Post-Stroke
Neurologic			
- Ischemic Stroke	2/23 (9%)	24, 125	20, 22
- Hemorrhagic Stroke	11/23 (48%)	167 [31-656]*	1 [0-62]*
Non-Neurologic			
- Right Heart Failure	3/23 (13%)	18, 123, 270	15, 84, 33
- Infection	3/23 (13%)	458, 494, 713	327, 165, 204
- Bleeding	2/23 (9%)	108,661	2, 478
- Pump Thrombosis	1/23 (4%)	411	303
- Respiratory Failure	1/23 (4%)	117	114


*Median [Range]




Survival Post-Implant by Subtype: Ischemic vs. Hemorrhagic















19






20





Survival Post-Stroke





Treatments of Stroke (excludes multiple strokes)

Treatment	Patients
Ischemic	n=20
Anticoagulation/Antiplatelet Intensification	11 (55%)
Anticoagulation/Antiplatelet Continuation	7 (35%)
Intra-arterial Embolectomy	0 (0%)
Other*	2 (10%)
Ischemic with Hemorrhagic Component/Conversion	n=5
Anticoagulation/Antiplatelet Hold	5 (100%)
Hemorrhagic	n=16
Anticoagulation/Antiplatelet Hold	5 (31%)
Anticoagulation/Antiplatelet Reversal ⁺	6 (38%)
Surgical†	3 (19%)
None	4 (25%)
*One patient treated with FFP due to INR > 7. †Two patien both anticoagulation reversal and surgery	ts treated with



23

Conclusions

- The use of the HeartMate 3 magnetically levitated LVAD in patients with advanced heart failure lowers stroke rates when compared with the axial flow HeartMate II pump
- Clinical trials of LVAD therapy must not selectively report functionally disabling stroke rates; rather they must primarily consider overall stroke rates due to the similar prognostic implications of either non-disabling or disabling strokes
- We also highlight the importance of the need to develop aggressive treatment algorithms for stroke events, specific to LVAD therapy in an effort to reduce subsequent disability and mortality



FRAME OF REFE		Anderster of Sydneys Luffish Productors	Date No.
in the third	-	Ingrown Ingenities function of these Ratio (Chang., Articleum	- tatle
in-Davi Alternationali d'ur Dosenado Mosthernal ur Talendhernational			
Industrial Philippe		b Burk	OF THE AR
Perspective		Long Rescaling Hilds in Cardinescular Ref.	International Property lies
Interest Inglicities of Transathetic Artic Sale Rep	the second	and Thermos	
n Policels al Internación Surgica Rob Mil Assessio - Ar Canari		CML.7368	
			THE PLAT
DEIGINAL RESEARCH ART		POLCY HONT	1.1.1
Sainlauken af Salmatad 10-bez Nati of Neurost Haav Dente and Neurost Nati is a Secondary Proventier Nati	-	And pet Drug, Adventeration Instance of Te Sets-From an Elevabor Trat to Destude them	righter Strep 25 Aug 10 ang
Assertional . A./ Yourist		in an installed Papelation 17 Millional - Educationian	11.11
Pedicing In: 10 fear finite of Albertradenity Landson			
Name & Direct Againties The Direct FM Fragel (F In 2014) Rue is Ching	-	Cardining News And-Aude Care Sales Series Stage in SME	Content .
1999		for Biologen and Biologet Services) Parc's of Samber Agenesis for Seat Mark	Expension.
Selected .		Witete	
But Feddlan to the Tere W?		Highlights From Major Manfings	
A.0000		Highlights of the Strengt Lincolds Meeting of	The Next Table
Interactioni Regardiencian & Property Nath Tarter for Laboration Restation of Restation of Restations, Street	for the	Society of America 2018 All Street and J Contenting	
and Regardio	_		
Witcon, 2 Advant			AND TRACE
Editorial .	_	806-Dallenge When is the Edget Laster?	
Intracendent Honorrhage, Racial Enganties, and to Love	-	All de Lores and Willer Sale	
all later		COMP.	SPOROFIC
Onited Subserves in 2012 Subdees and Mulde With Name		Restant Later	of a desired
Aust Roome From 191, one and Matthe Access Country Non-Nam Televolg of the Galaci Reputatio Heart Disco		"Reduced Dear" or "Advance Dear" 1 do in	-
Reports the NUMBER States		Martally for Falsards Will Salhares: Dirate 1	- Brath Caratria
Contes . del Mayor		LBL AFTury	
		-	
er tru Toroy			American

Simultaneously Published online at http://circ.ahajournals.org

THANK YOU to MOMENTUM 3 INVESTIGATORS, LVAD COORDINATORS and The HEART TEAM

DISCLOSURES: THE MOMENTUM 3 TRIAL IS SPONSORED BY ABBOTT



Abbott

6101 Stoneridge Dr., Pleasanton, CA 94588 USA, Tel: 1 925 847 8600 Cardiovascular.Abbott/HeartMate3

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3[™] LVAS Indications: The HeartMate 3[™] Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3[™] LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3[™] LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

[™] Indicates a trademark of the Abbott group of companies.

‡ Indicates a third-party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved. MAT-2004336 v2.0 | Item approved for U.S. use only.

